[1] CAI BQ, YAN XX, et al.Expert Consensus on Acute Exacerbation of Chronic Obstructive Pulmonary Disease in the People’s Republic of China(2023 Revised Edition)[J]. Int J Respir, 2023, 43(2): 132-149. [2] ELLIOTT WJ.Drug interactions and Drugs that Affect Blood Pressure[J]. J Clin Hypertens (Greenwich), 2006, 8(10): 731-737. [3] SARATHY H, SALMAN LA, LEE C, et al.Evaluation and Management of Secondary Hypertension[J]. Med Clin North Am, 2022, 106(2): 269-283. [4] SUNDERRAM J, ANDROULAKIS IP.Molecular Mechanisms of Chronic Intermittent Hypoxia and Hypertension[J]. Crit Rev Biomed Eng, 2012, 40(4): 265-278. [5] NESTEROV V, BERTOG M, CANONICA J, et al.Critical Role of the Mineralocorticoid Receptor in Aldosterone-dependent and Aldosterone-independent Regulation of ENaC in the Distal Nephron[J]. Am J Physiol Renal Physiol, 2021, 321(3): F257-F268. [6] GOODWIN JE, GELLER DS.Glucocorticoid-induced Hypertension[J]. Pediatr Nephrol, 2012, 27(7): 1059-1066. [7] PRZYBYCIŃSKI J, DROŻDŻAL S, DOMAŃSKI L, et al. Role of Endothelial Glucocorticoid Receptor in the Pathogenesis of Kidney Diseases[J]. Int J Mol Sci, 2021, 22(24): 13295. [8] VEROUTI S, HUMMLER E, VANDERRIELE PE.Role of Glucocorticoid Receptor Mutations in Hypertension and Adrenal Gland hyperplasia[J]. Pflugers Arch, 2022, 474(8): 829-840. [9] POFI R, CARATTI G, RAY DW, et al.Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good from the Bad?[J]. Endocr Rev, 2023, 44(6): 975-1011. [10] CHEN ZY, GE JB, HUANG K, et al.Consensus of Chinese Experts on Standardized Diagnosis and Treatment Under the Joint Management of“three highs”(2023)[J]. Chinese Video Journal of Cardiology(中华心血管病杂志), 2023, 6(1): 1-11. [11] KUPCZYK D, BILSKI R, KOZAKIEWICZ M, et al.11β-HSD as a New target in Pharmacotherapy of Metabolic Diseases[J]. Int J Mol Sci, 2022, 23(16): 8984. |